Jazz Pharmaceuticals

This phase 2 trial is testing a drug called ONC206 in 90 people with advanced pheochromocytoma or paraganglioma, rare tumors of the adrenal glands. Participants must have tumors that cannot be removed by surgery and have not responded to or cannot have standard treatments. The st…

This phase 2 trial tests a drug called zanidatamab in about 200 adults with advanced HER2-positive cancers, including breast, lung, stomach, and others. Participants have already tried at least one standard treatment. The study measures how many tumors shrink or disappear. Zanida…

This study tests whether adding the drug zanidatamab to standard chemotherapy (with or without an immunotherapy) can help people with advanced HER2-positive bile duct cancer live longer without their cancer growing. About 286 adults with inoperable or metastatic bile duct cancer …

This study tests whether adding zanidatamab to standard chemotherapy can completely eliminate cancer in people with early-stage HER2-positive breast cancer before they have surgery. About 125 participants with stage II or III disease will receive the combination, and doctors will…

This early-phase study is testing a new drug called JZP815 in people with advanced or spreading solid tumors that have specific changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 332 adults who h…

This Phase 3 trial tests the drug ONC201 (dordaviprone) in people newly diagnosed with a rare brain cancer called H3 K27M-mutant diffuse glioma. Participants receive either ONC201 or a placebo after completing standard radiotherapy. The study aims to see if the drug helps them li…

This phase 3 trial is testing whether a new drug called zanidatamab, given with chemotherapy, works better than the current standard treatment (trastuzumab plus chemo) for people with metastatic HER2-positive breast cancer that has worsened after prior therapy. About 550 adults w…

This study tests a drug called lurbinectedin in children and young adults (ages 2 to 30) with Ewing sarcoma that has returned or not responded to prior treatments. The first part finds the safest dose, and the second part checks if the drug shrinks tumors. About 60 participants w…

This early-stage study tests an oral drug called ONC206 in adults with brain tumors that have come back. The main goal is to find the safest dose and check for side effects. About 102 participants will take the drug once or several times a week.

This early-stage trial is testing an investigational drug called JZP898, both by itself and together with the immunotherapy pembrolizumab, in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety, find t…

This study tests a liquid form of cannabidiol (CBD) in 100 people aged 12 to 75 who have focal-onset seizures. CBD is already approved for certain rare seizure disorders, and researchers want to see if it can also help reduce focal seizures. Participants will take CBD oil by mout…

This study follows pregnant women who have taken Epidiolex (a cannabidiol medicine for seizures) to see if it affects pregnancy outcomes or the baby's health up to 12 months after birth. Researchers will track complications like birth defects, miscarriage, and preterm delivery. T…

This early-stage study tests a new drug, JZP047, in 86 healthy adults aged 18 to 55. The goal is to check its safety, how the body handles it, and whether food affects its absorption. Participants receive either a single dose of JZP047 or a placebo. This research does not aim to …